TP53 and in situ carcinoma: It may be that doxorubicin-treated cancer cells have an initial induction of ROS that triggers downstream processes of senescence and further ROS production, but in CIS-resistant cells these events (including further ROS production) are blocked by both the expression of Mcl-1 and absence of p53 - both common features of cancer.